| Literature DB >> 28815164 |
Ali Humadi1, Tat Chao2, Sulaf Dawood1, Mark Tacey3, Arshad Barmare1, Brian Freeman4.
Abstract
STUDYEntities:
Keywords: laminoplasty; meta-analysis; myelopathy
Year: 2017 PMID: 28815164 PMCID: PMC5546685 DOI: 10.1177/2192568217701721
Source DB: PubMed Journal: Global Spine J ISSN: 2192-5682
Figure 1.Article selection flow chart.
PICO Table Describing Inclusion and Exclusion Criteria.
| Study Component | Inclusion | Exclusion |
|---|---|---|
| Population |
Humans Age >18 years Patients undergoing laminoplasty with or without mini-plate fixation for cervical spondylotic myelopathy |
Animal studies Pediatrics Non-laminoplasty studies Less than 10 patients Less than 18-month follow-up |
| Intervention(s) |
Laminoplasty with or without mini-plate fixation for cervical spondylotic myelopathy |
Other methods of treatment of cervical spondylotic myelopathy |
| Outcomes |
Japanese Orthopaedic Association scores, Hirabayashi recovery rate), Nurick scores, and range of movement |
No outcome score mentioned or use of different outcome |
| Publication |
Studies published in English in peer-reviewed journals |
Abstracts, editorials, letters Duplicate publications of the same study that do not report on different outcomes Single reports from multicenter trials Studies with less than 10 patients or less than 18-month follow-up Meeting abstracts, presentations, or proceedings Narrative reviews Articles identified as preliminary reports when results are published in later versions |
| Study design |
All study design except case reports and review articles |
Case reports |
Summary of Studies Included for Analysisa,b.
| Author | Year | Journal | Study Type | Evidence Level | Laminoplasty Patients | Percentage Male (%) | Mean Age | Follow-up Period (Months), Mean (SD) | Preoperative JOA Score, Mean (SD) | Postoperative JOA Score, Mean (SD) | Hirabayashi Recovery Rate (%), Mean (SE) | Preoperative Nurick Score, Mean (SD) | Postoperative Nurick Score, Mean (SD) | Preoperative ROM (°), Mean (SD) | Postoperative ROM (°), Mean (SD) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||||
| Agrawal | 2004 |
| Retrospective review | 3 | 24 | 87 | 56.73 | 22 | N/A | N/A | N/A | 4.04 | 3.16 | N/A | N/A |
| Mizuno | 2006 |
| Retrospective comparative | 3 | 10 | N/A | N/A | 24 | N/A | N/A | N/A | N/A | N/A | 32.1 ± 13.0 | 26.2 ± 11.0 |
| Orabi | 2008 |
| Prospective trial | 2 | 22 | 73 | 62.6 | 21.1 | 7.5 | 15.6 | 85.3 | N/A | N/A | N/A | N/A |
| Dimar | 2009 |
| Retrospective review | 3 | 104 | 61 | 59.2 | 50.2 ± 19 | N/A | N/A | N/A | 2.11 ± 0.85 | 0.63 ± 0.69 | N/A | N/A |
| Asgari | 2009 |
| Prospective case series | 2 | 13 | 85 | 49 | 33 | 11 | 12 | 16.7 | N/A | N/A | N/A | N/A |
| Petraglia | 2010 |
| Retrospective review | 3 | 40 | 70 | 57 | 31.3 ± 15.1 | N/A | N/A | N/A | 2.08 | 0.93 | N/A | N/A |
| Jiang* | 2012 |
| Retrospective comparison | 3 | 38 | 63 | 56 | 19 | 9.0 ± 0.7 | 13.3 ± 0.9 | 53.75 | N/A | N/A | 49.6 ± 6.9 | 40.1 ± 4.0 |
| Chen*+ | 2012 |
| Retrospective review | 3 | 29 | 86 | 61.2 | 23.3 ± 7.2 | 9.48 ± 2.28 | 13.79 ± 1.78 | 57.48 (3.07) | N/A | N/A | 39.48 ± 8.74 | 36.07 ± 9.82 |
| Jiang* | 2012 |
| Retrospective review | 3 | 26 | 65 | 62 | 22 | 9.1 ± 1.5 | 13.9 ± 1.6 | 60.7 (2.45) | N/A | N/A | 30.5 ± 8.2 | 27.5 ± 8.7 |
| Yang* | 2013 |
| Retrospective review | 3 | 75 | 75 | 57.19 | 24 | 8.91 ± 1.23 | 13.55 ± 1.34 | 57.29 (1.78) | 2.40 ± 0.96 | 0.65 ± 0.71 | 29.88 ± 6.43 | 24.95 ± 6.24 |
| Fujimori | 2013 |
| Retrospective comparison | 3 | 60 | 67 | 63.1 | 20.9 ± 13.1 | 12.8 ± 3.1 | 14.5 ± 2.7 | 40.48 | 2 | 1 | 32.7 | 24.4 |
| Yang* | 2013 |
| Retrospective review | 3 | 42 | 86 | 61.4 | 23.2 ± 7.4 | 9.5 ± 1.8 | 13.9 ± 1.5 | 58.9 (2.75) | N/A | N/A | N/A | N/A |
| Hyun* | 2013 |
| Prospective cohort | 2 | 18 | 67 | 56.4 | 68.1 | 10.1 ± 3.5 | 13.9 ± 2.0 | 55.0 (4.43) | N/A | N/A | 39.9 ± 11.2 | 24.5 ± 10.1 |
|
| |||||||||||||||
| Iwasaki* | 2007 |
| Retrospective review | 3 | 66 | 77 | 57 | 122.4 | 9.2 | 13.7 | 55 (7.45) | N/A | N/A | N/A | N/A |
| Matsumoto* | 2008 |
| Retrospective review | 3 | 82 | 76 | 62.7 | 21.6 | 9.7 ± 3.1 | 13.7 ± 2.4 | 53.9 (3.30) | N/A | N/A | N/A | N/A |
| Yang | 2008 |
| Prospective series | 2 | 12 | 58 | 62 | 32 | 6.9 ± 3 | 13 ± 1.6 | 60.4 | N/A | N/A | N/A | N/A |
| Suzuki* | 2009 |
| Prospective cohort | 2 | 98 | 70 | 59.6 | 81.6 | 11.1 ± 3.96 | 14.3 ± 1.98 | 50.1 (3.8) | N/A | N/A | N/A | N/A |
| Kotani* | 2009 |
| Retrospective comparative | 3 | 84 | 76 | 62 | 32 | 9.1 ± 3.5 | 14.6 ± 1.6 | 69 (1.64) | N/A | N/A | N/A | N/A |
| Okada* | 2009 |
| Prospective RCT | 2 | 35 | 80 | 59.9 | 27.6 | N/A | 14.2 ± 1.6 | 52.8 (4.75) | N/A | N/A | N/A | N/A |
| Sivaraman | 2010 |
| Prospective comparison | 2 | 25 | 56 | 62.4 | 24 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Liu* | 2011 |
| Retrospective comparative | 3 | 27 | 59 | 56 | 27.47 ± 11.06 | 8.59 ± 2.98 | 13.67 ± 2.7 | 59.54 (5.65) | N/A | N/A | 40.44 ± 10.25 | 36.15 ± 10.58 |
| Chen*+ | 2012 |
| Retrospective review | 3 | 25 | 80 | 63.2 | 25.8 ± 8.5 | 9.24 ± 1.42 | 13.60 ± 0.87 | 56.10 (?) | N/A | N/A | 38.52 ± 9.99 | 29.52 ± 10.13 |
| Jiang+ | 2012 |
| Retrospective comparison | 3 | 23 | 70 | 59 | 19 | 9.2 ± 1.0 | 13.1 ± 0.7 | 50 | N/A | N/A | 51.3 ± 8.1 | 41.4 ± 5.1 |
| Seng* | 2013 |
| Retrospective analysis | 3 | 52 | 77 | 60.6 | 24 | 11 ± 3 | N/A | 53.1 (5.87) | N/A | N/A | N/A | N/A |
aAll studies were considered used for qualitative analysis, and only studies marked with asterisks were used for quantitative analysis.
bStudies marked with “*” and shaded gray = studies included in the meta-analysis. “+” = Same paper.
Figure 2.Forest plot comparing the Hirabayashi ES (%) at the end of follow-up for plate studies. ES, effect size; 1-V, inverse variance; D+L, DerSimonian and Laird method, weights are estimated from random effects analysis and contribute to D+L overall estimate.
Figure 3.Forest plot comparing the Hirabayashi ES at the end of follow-up for no-plate studies. ES, effect size; 1-V, inverse variance; D+L, DerSimonian and Laird method, weights are estimated from random effects analysis and contribute to D+L overall estimate.
Figure 4.(A) Funnel plot of Hirabayashi ES at the end of follow-up for plate studies. (b) Funnel plot of Hirabayashi ES at the end of follow-up for no-plate studies.